Picture [iito] Männer Ballett 650x80px
Document › Details

Quotient Bioresearch Ltd.. (9/19/11). "Press Release: Quotient Bioresearch Announces First Use of Bruker MALDI Biotyper for Bacterial Identification".

Organisations Organisation Quotient Bioresearch Ltd.
  Group Quotient Bioresearch (Group)
  Organisation 2 Bruker Daltonik GmbH
  Group Bruker Corporation (Group)
Products Product MALDI Biotyper system (MBT)
  Product 2 drug development services
Persons Person Morrissey, Ian (Quotient Bioscience 201109 Director of Microbiology at Quotient Bioresearch)
  Person 2 Parker, Craig (Bruker 201109 Global Market Manager for Microbiology at Bruker Daltonics)

Quotient Bioresearch has today announced its adoption of Bruker's MALDI Biotyper for bacterial identification, following a successful year-long trial.

The announcement, made at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 17-20, Chicago, US) where Quotient will be presenting a series of posters, places the company in a unique position as the first GLP laboratory to adopt the technology for routine bacterial identification as part of its portfolio of services for antimicrobial development.

Dr Ian Morrissey, Director of Microbiology at Quotient, commented: "Quotient's expert Bioanalytical Sciences team is a fusion of microbiology, immunochemistry and mass-spectrometry specialists, which means we are perfectly placed to embrace this technology."

Delivering rapid and precise identification, Bruker's MALDI Biotyper technology enables Quotient to identify many thousands of organisms a year for antibiotic resistance surveillance, in a much more efficient and accurate manner than traditional identification methods.

Craig Parker, Global Market Manager for Microbiology at Bruker Daltonics, said: "It's great to see Quotient embracing our MALDI Biotyper technology and encompassing it within its own technical work."

Ian added: "The trial period of Bruker's MALDI Biotyper has proved very successful and we are confident that this technology represents the future of bacterial identification, and Quotient is proud to be at the forefront of this exciting field."

Quotient will be presenting two posters on MALDI-ToF technology at ICAAC.
'D-1285 - Large Scale Performance Evaluation of MALDI-ToF MS in a Central Reference Laboratory Setting' is the largest industry study into MALDI-ToF and 'D-1284 - Rapid Identification of Veterinary Enterococci by MALDI-ToF MS' analyses how MALDI-ToF technology can aid better identification of bacteria over traditional industry methods.

Quotient Bioresearch is exhibiting at booth number 335 during the conference. Bruker Daltonics is exhibiting at booth number 813.

Record changed: 2016-03-20


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Quotient Bioresearch (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Fighting Customers 650x80px

» top